Uncertain Reg Climate Could Turn Medtech Investors Off Europe
A key stage in the EU process of adopting and implementing new regulations for medical devices and diagnostics was reached with the recent series of debates – the Trilogues – between the European Commission, the Parliament and Council of the EU. But matters are poised on a knife edge and are not always moving as quickly as or in the way local industry wants.
You may also be interested in...
Are medtech regulators and authorities in wider Europe – including Russia – setting market access barriers too high, risking investment in innovation and potentially denying patients access to modern care? European Diagnostic Manufacturers Association (EDMA) representative Christian Parry fears so, in this second half of our industry update from the 2015 European MedTech Forum.
The proposed EU In Vitro Diagnostics Regulation will introduce a tougher system of regulation that will bring increased intervention of notified bodies into the compliance pathway. Companies selling IVDs into the EU market are beginning to factor in rising costs and other challenges before it takes effect.
The UK has added important new capabilities to its COVID-19 monitoring and control effort and those running it promise a “world class system” by late summer.